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Abstract
Human Polynucleotide Phosphorylase (hPNPaseold-35 or PNPT1) is an evolutionarily conserved 39R59 exoribonuclease
implicated in the regulation of numerous physiological processes including maintenance of mitochondrial homeostasis,
mtRNA import and aging-associated inflammation. From an RNase perspective, little is known about the RNA or miRNA
species it targets for degradation or whose expression it regulates; except for c-myc and miR-221. To further elucidate the
functional implications of hPNPaseold-35 in cellular physiology, we knocked-down and overexpressed hPNPaseold-35 in human
melanoma cells and performed gene expression analyses to identify differentially expressed transcripts. Ingenuity Pathway
Analysis indicated that knockdown of hPNPaseold-35 resulted in significant gene expression changes associated with
mitochondrial dysfunction and cholesterol biosynthesis; whereas overexpression of hPNPaseold-35 caused global changes in
cell-cycle related functions. Additionally, comparative gene expression analyses between our hPNPaseold-35 knockdown and
overexpression datasets allowed us to identify 77 potential ‘‘direct’’ and 61 potential ‘‘indirect’’ targets of hPNPaseold-35 which
formed correlated networks enriched for cell-cycle and wound healing functional association, respectively. These results
provide a comprehensive database of genes responsive to hPNPaseold-35 expression levels; along with the identification new
potential candidate genes offering fresh insight into cellular pathways regulated by PNPT1 and which may be used in the
future for possible therapeutic intervention in mitochondrial- or inflammation-associated disease phenotypes.
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Introduction
Ribonucleases (RNases) are one of the central players involved
in the regulation of post-transcriptional control of gene expression
in both prokaryotes and eukaryotes [1,2]. They are divided into
two main categories, endo- and exo-ribonucleases. Depending on
the direction of degradation, exoribonucleases can be further
classified as 59R39 or 39R59 exoribonucleases [3]. Numerous
exoribonucleases identified in bacteria, Archaea and Eukarya have
been placed under six major superfamilies, RBN, RNR, DEDD,
PDX, RRP4 and 5PX [4,5]. Of these, the PDX family is the only
one whose members use inorganic phosphate to generate
nucleotide diphosphates instead of hydrolytic cleavage [5].
Polynucleotide phosphorylase (PNPase) is an evolutionarily
conserved phosphorolytic 39R59 exoribonuclease that belongs to
the PDX family of proteins [4] and it plays a major role in RNA
metabolism in bacteria, plants and humans. The protein encoded
by this gene consists of five conserved classical domains: two
RNase PH domains, a a–helical domain and two RNA binding
domains KH and S1 [6]. The human homolog of this gene
(hPNPaseold-35) was identified in an overlapping pathway screen
(OPS) intended to identify upregulated transcripts in terminally
differentiated human melanoma cells and senescent progeroid
fibroblasts [7].
Human polynucleotide phosphorylase (hPNPaseold-35) is encoded
by the PNPT1 gene mapping to chromosome 2p15-2p16.1 and has
been characterized as a type I IFN (IFN-a/b)-inducible early
response gene [7,8]. Numerous endeavors over the past decade have
enriched our comprehension of the workings of this exoribonu-
clease. It has become increasingly clear over the years that the
various physiological functions of this enzymatic protein are not
restricted to a single cellular compartment, in this case the
mitochondrial inter membrane space (IMS) where it is primarily
located [9,10]. In the cytoplasm this protein performs a myriad of
functions, which include but are not restricted to degradation of
mRNA and miRNA species [11,12]. Adenoviral-mediated overex-
pression of hPNPaseold-35 causes growth inhibition of normal and
cancer cells characterized by morphological changes associated with
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senescence, G1/S or G2/M cell-cycle arrest and apoptosis
[11,13,14,15]. The ability of hPNPaseold-35 to selectively degrade
c-myc mRNA through its exoribonucleolytic activity has been
identified as a key molecular mechanism mediating the growth
suppressive effects of hPNPaseold-35, since overexpression of c-myc
could only partially rescue these effects [11]. Apart from mRNA
degradation, hPNPaseold-35 has also been identified as a direct
regulator of mature miRNA species, specifically miR-221 that
targets the cell cycle inhibitor p27Kip1 [12,16]. Both these
specialized functions of hPNPaseold-35 also implicate it as a direct
mediator of IFN-b-induced growth inhibition [12,17]. Another
novel function of hPNPaseold-35 is its ability to generate double-
stranded RNA (dsRNA) through a currently unknown mechanism,
which ultimately leads to apoptosis of cells due to the activation of
dsRNA-dependent protein kinase (PKR) [13].
Apart from the above-mentioned cytoplasmic functions that
focus on its physiological roles in the regulation of growth
inhibition and senescence, numerous roles of hPNPaseold-35 have
been revealed that are central to its location in the mitochondria
[16,18,19,20]. Overexpression of hPNPaseold-35 induces reactive
oxygen species (ROS) production in the mitochondria resulting in
the expression of pro-inflammatory cytokines, which is a major
phenomenon linking hPNPaseold-35 to aging-related inflammation
[21,22]. The significance of hPNPaseold-35 in maintaining mito-
chondrial homeostasis, with a specific relevance to the electron
transport chain (ETC) components, has been revealed by
hPNPaseold-35 knockdown studies in cell systems and also in a
liver-specific knockout mouse model of hPNPaseold-35 [9,23]. There
are also studies providing evidence that hPNPaseold-35 is a regulator
of mitochondrial RNA import and plays a role in mtRNA
processing [23-27]. Recently hPNPaseold-35 has also been shown to
be present in the nucleus, and is associated with nEGFR protein,
which regulates the exoribonuclease activity of hPNPaseold-35 upon
exposure to ionizing radiations [28].
Most of what we know about hPNPaseold-35 today has been
gleaned from classical gain-of-function or loss-of-function exper-
iments and from comparative studies performed through lessons
acquired from its bacterial and plant counterparts [16,19,20].
Although these studies have been immensely valuable in illumi-
nating the importance of hPNPaseold-35 in various physiological
phenomena like senescence, growth-inhibition and mitochondrial
dynamics, little is known about the specific network of genes that
are involved in these processes or which might be dysregulated
when hPNPaseold-35 is aberrantly expressed. Moreover, when
evaluating its function as an exoribonuclease, we know of only
one mRNA and a single miRNA species that hPNPaseold-35 can
degrade directly, c-myc and miR-221, respectively. Such findings
led to our interest in trying to identify genes or gene networks that
are either potential direct degradation targets of hPNPaseold-35 or
regulated by hPNPaseold-35, respectively. In order to pursue this
objective, we performed gene expression analysis on human
melanoma cells in which hPNPaseold-35 was either silenced or
ectopically overexpressed. Studying the global gene expression
changes associated with hPNPaseold-35-knockdown or overexpres-
sion has provided valuable new insights regarding the functions of
this elusive exoribonuclease while also validating previously known
information. With the help of Ingenuity Pathway Analysis (IPA)
we have identified key biological functions and associated genes
that are deregulated in response to aberrant expression of
hPNPaseold-35. Additionally, comparative analysis of the knockdown
Figure 1. Generation of a melanoma cell culture model for hPNPaseold-35 expression. (A) Phase contrast LM (top) and GFP fluorescent
micrographs (bottom) of HO-1 melanoma cell lines following transduction with GFP expressing scrambled shRNA (HO-1 Csh) and hPNPaseold-35
shRNA1 (shown in clone 4; cl4) and 2 (shown is clone 9; cl9) expressing lentiviruses and selection with puromycin. qRT-PCR expression of
hPNPaseold-35 (hPNPaseold-35 knockdown) normalized to control (shScramble). Mean values normalized to a GAPDH internal reference; error bars
represent mean 6 S.E. of three replicate experiments. Anti-hPNPaseold-35 and EF1a loading control immunoblots. (B) qRT-PCR expression of
hPNPaseold-35 in HO-1 cells infected with Ad.hPNPaseold-35 normalized to cells infected with Ad.Vec for 36 h. Immunoblot showing hPNPaseold-35
overexpression compared to Ad.Vec post 36 hour of infection. Error bars represent mean 6 S.E of three replicate experiments. * P,0.02, *** P,0.001.
doi:10.1371/journal.pone.0076284.g001
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and overexpression datasets has allowed us to identify novel genes
that may be directly or indirectly regulated by hPNPaseold-35.
In summary, our present studies interrogated the global
implications of hPNPaseold-35 dysregulation and now provide a
comprehensive database that can be further used not only to
understand the biological functions of hPNPaseold-35 but also to
identify candidate direct degradation targets such as c-myc and
miR-221.
Materials and Methods
Cell culture
The human melanoma cell line HO-1 [29–31] was initially
provided by Dr. Eliezer Huberman (Argonne National Labora-
tories, IL) maintained in Dulbecco’s Modified Eagle Medium
(DMEM; Invitrogen Life Technologies) supplemented with 10%
fetal bovine serum (FBS; Sigma) and 5% penicillin/streptomycin
(Gibco). The melanoma cell line WM35 [32–35], provided by Dr.
Meenhard Herlyn (Wistar Institute) was maintained in
MCDB153:Leibovitz’s L15 (4:1) pH 7.4 supplemented with 2%
FBS and CaCl2 (1.68 mM, Sigma). The hPNPase
old-35-knockdown
stable cell lines were maintained in growth medium as described
with the addition of 200 ng/ml (in case of HO-1 cells) or 300 ng/
ml (in case of WM35 cells) of the selective antibiotic puromycin.
The melanoma cell lines C8161 and MeWo were cultured as
previously described [11,12]. All cell lines were maintained in a
5% CO2 95% O2 humidified incubator at 37uC. 0.5% Trypsin-
EDTA (10X) solution was purchased from Gibco and 1X
Dulbecco’s Phosphate-Buffered Saline (DPBS) from Corning
Cellgro.
Expression constructs, stable cell lines and viral infections
Lentiviral constructs (pGIPZ) expressing GFP were purchased
from Open Biosystems. The constructs contained non-silencing
short hairpin RNA (shRNA) or shRNAs against hPNPaseold-35
(PNPshRNA-1: clone ID V2LHS_17644, Mature Sense: GGC
AACAGGAAATTAGAAA, Mature Antisense: TTTCTAATTT
CCTGTTGCC; PNPshRNA-2: clone ID V2LHS_159887, Ma-
ture Sense: CAATAGGATTGGTCACCAA, Mature Antisense:
TTGGTGACCAATCCTATTG). Lentiviruses encoding the dif-
ferent shRNAs were produced by cotransfecting the HEK-293T
packaging cells with the appropriate pGIPZ constructs and the
Trans-lentiviral Packaging Mix (Open Biosystems) according to
the manufacturer’s protocol. The supernatants containing the
lentiviral particles were harvested 48 hours after transfection,
concentrated by centrifugation and frozen at 280uC as aliquots.
1ml of the above viral suspension was used to transduce 36105
HO-1 human melanoma cells grown in 6-cm dishes supplemented
with 10 mg/ml polybrene. 48 hours post-transduction cells were
trysinized and replated at a low density (1:5) and complete media
was added supplemented with positive selection marker puromy-
cin to establish stable shRNA expressing single clones over a
period of two weeks. Single clones isolated for PNPshRNA-1 and
PNPshRNA-2 were screened to assess the level of knockdown at
both the RNA and protein levels and the HO-1 clones with
maximum hPNPaseold-35 knockdown were used for microarray
Figure 2. Venn diagrams representing number of genes significantly altered when hPNPaseold-35 is knocked down or overexpressed
in human melanoma cells. Shown are total number of dysregulated genes (A), genes ‘‘directly’’ (B) and ‘‘indirectly’’ (C) regulated by hPNPaseold-35.
doi:10.1371/journal.pone.0076284.g002
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analyses (we used one of our HO-1 PNPshRNA-1 clones for this
purpose).
The construction and purification of replication-incompetent
adenovirus encoding hPNPaseold-35 (Ad.hPNPaseold-35) has been
described previously [7,11]. The empty vector Ad.vec was used
as a control. For all adenoviral experiments, 16105 cells were
grown in 6-cm dishes and infected after 24 hours with Ad.vec or
Ad.hPNPaseold-35 at a final m.o.i. of 5000 vp/cell diluted in 1 ml of
serum-free media. After 6 hours of infection with shaking every 15
minutes, complete media was added and cells were harvested at
the required time points (e.g., 36 hours post-infection) for
microarray analysis, RNA or protein isolation.
RNA extraction, quality assessment and Microarray
analyses
Total RNA from the hPNPaseold-35-knockdown cell line (HO-1
melanoma cells stably expressing shRNA-1 against hPNPaseold-35),
HO-1 cells expressing non-silencing control shRNA, and HO-1
cells infected with Ad.hPNPaseold-35 or Ad.vec for 36 hours was
isolated from cell lysates in TRIZOL reagent (InvitrogenTM Life
Technologies, Carlsbad, CA). Cell lysates were subjected to an
automated extraction method using the MagMAXTM-96 for
Microarrays Total RNA Isolation Kit (Ambion/InvitrogenTM
Life Technologies, Carlsbad, CA) on the MagMAXTM Express
Magnetic Particle Processor (Applied Biosystems/InvitrogenTM
LifeTechnologies, Carlsbad, CA).
Gene expression profiles were ascertained using GeneChipH
Human Genome U133A 2.0 (HG-U133A 2.0) arrays (Affymetrix,
Santa Clara, CA) as previously described. Every chip was scanned
at a high resolution, with pixelations ranging from 2.5 mm down to
0.51 mm, by the Affymetrix GeneChipH Scanner 3000 according
to the GeneChipH Expression Analysis Technical Manual
procedures (Affymetrix, Santa Clara, CA). After scanning, the
raw intensities for every probe were stored in electronic files
(in.DAT and.CEL formats) by the GeneChipH Operating
Software (GCOS) (Affymetrix, Santa Clara, CA). The overall
quality of each array was assessed by monitoring the 39/59 ratios
Figure 3. Functional analysis of genes dysregulated as a result of hPNPaseold-35 depletion. (A) The biological functions and states
associated with genes differentially expressed when hPNPaseold-35 is knocked down in human melanoma cells. (B) Toxicologically related
functionalities and pathways associated with genes dysregulated (proportions shown in graphs) after hPNPaseold-35 knockdown in melanoma cells, as
identified by IPA Toxicogenomic Analysis.
doi:10.1371/journal.pone.0076284.g003
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Table 1. List of genes which are significantly altered as a result of hPNPaseold-35 stable knockdown, and are associated with
cholesterol biosynthesis, according to IPA Toxicogenomic Analysis.
Gene Symbol Gene Name Fold Change Affymetrix ID
ACAT2 acetyl-CoA acetyltransferase 2 21.29 * 209608_s_at
DHCR7 7-dehydrocholesterol reductase 21.51 ** 201790_s_at
EBP emopamil binding protein (sterol isomerase) 21.22 * 213787_s_at
FDFT1 farnesyl-diphosphate farnesyltransferase 1 21.23 * 210950_s_at
FDPS farnesyl diphosphate synthase 21.17 * 201275_at
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 21.42 *** 202539_s_at
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 21.56 *** 221750_at
IDI1 isopentenyl-diphosphate delta isomerase 1 21.92 *** 208881_x_at
LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 21.29 * 202245_at
MVD mevalonate (diphospho) decarboxylase 21.24 * 203027_s_at
SC5DL sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. cerevisiae)-like 21.26 * 211423_s_at
SQLE squalene epoxidase 21.37 ** 209218_at
doi:10.1371/journal.pone.0076284.t001
Table 2. List of ETC components which are significantly altered as a result of hPNPaseold-35 stable knockdown, and are associated
with mitochondrial dysfunction, according to IPA Toxicogenomic Analysis.
ETC components Gene symbol Gene name Fold change Affymetrix ID
Complex I NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kDa 21.11 * 209224_s_at
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9 kDa 21.32 *** 218563_at
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19 kDa 21.14 * 218160_at
NDUFA13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 1.22 ** 220864_s_at
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8 kDa 21.07 * 202077_at
NDUFAF1 NADH dehydrogenase (ubiquinone) complex I, assembly factor 1 21.09 * 204125_at
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15 kDa 21.09 * 218226_s_at
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa 21.09 * 203621_at
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18 kDa 1.36 ** 202839_s_at
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75 kDa (NADH-coenzyme
Q reductase)
21.22 *** 203039_s_at
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49 kDa (NADH-coenzyme
Q reductase)
21.18 ** 201966_at
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30 kDa (NADH-coenzyme
Q reductase)
21.10 * 201740_at
Complex II SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 21.11 * 202675_at
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein,
15 kDa
21.19 * 210131_x_at
Complex III UQCR10 ubiquinol-cytochrome c reductase, complex III subunit X 21.13 * 218190_s_at
UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI 1.22 ** 202090_s_at
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 21.32 *** 208909_at
Complex IV COX6B1 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) 21.31 *** 201441_at
Cytochrome c oxidase COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) 21.80 *** 204570_at
SURF1 surfeit 1 21.17 ** 204295_at
Complex V ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1,
cardiac muscle
21.12 ** 213738_s_at
ATP synthase ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide21.10 * 201322_at
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma
polypeptide 1
21.40 *** 213366_x_at
doi:10.1371/journal.pone.0076284.t002
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for a housekeeping gene (GAPDH) and the percentage of
‘‘Present’’ genes (%P); where arrays exhibiting GAPDH 39/
59,3.0 and %P.40% were considered good quality arrays [36].
All experiments were done in biological triplicates. The micro-
array data generated for this study are available online at the Gene
Expression Omnibus repository under the accession number
GSE46884.
Statistical Analysis, IPA and functional classification of
genes
The Robust Multiarray Average method (RMA) was used for
normalization and generating probe set expression summaries for
the gene expression assays. To identify genes significantly altered
among the different conditions (i.e., hPNPaseold-35 down-regulation
and up-regulation), t-tests were performed for each cell type. To
adjust for multiple hypothesis testing, the resulting p-values were
used to obtain the false discovery rates using the q-value method.
Genes were considered significant using an FDR of 5%. All
analyses were performed in the R statistical environment using
functions provided by the BioConductor packages [36,37].
In order to categorize biological functions related to gene
expression altered by hPNPaseold-35 in our microarray analyses, we
used the Ingenuity Pathway Analysis (IPA, IngenuityH Systems,
http://www.ingenuity.com) [38,39]. Genes were considered
differentially expressed if they had q-values#0.05. The Affymetrix
probe set IDs of significantly altered genes identified through the
statistical analysis described above in both the hPNPaseold-35-
knockdown and overexpression scenarios, along with their
associated p- and q-values were uploaded into IPA and analyses
performed.
The ToppFun function of the ToppGene suite of web
applications [40] was used for the functional enrichment of the
hPNPaseold-35-directly and indirectly regulated genes. The HGNC
symbols for both the gene lists were uploaded and a FDR
correction threshold of 5% was set for the subsequent functional
enrichment analyses. The Gene Ontology (GO) categories
(molecular function, biological process, and cellular component),
biological pathway and gene and miRNA families were considered
for analyses.
In order to further validate if genes regulated by alterations in
hPNPaseold-35 expression formed gene interaction networks, the
gene symbols for the potential hPNPaseold-35-‘‘directly’’ and -
‘‘indirectly’’ regulated genes were uploaded into GeneMANIA
(http://www.genemania.org), a web interface for generating
interactive functional association networks [41]. This resource
utilizes multiple external datasets, including protein-protein
interactions and published microarray datasets, to form networks
of potential gene-gene interactions. The interactive functional
association networks obtained were generated based on co-
expression, biological pathways, predicted association, genetic
interactions, physical interactions and co-localization functional
association data. The networks were generated using the query-
dependent automatically selected weighting method.
cDNA synthesis and quantitative real-time RT-PCR (qRT-
PCR)
Total RNA was harvested from the hPNPaseold-35-knockdown
and control stable cell lines and from the adenovirus infected HO-
1 cells using the RNeasy purification kit (Qiagen). The quality and
concentrations of isolated RNA samples were assessed using the
NanoDrop 2000 (Thermo Scientific). 2 mg of RNA was used in a
total volume of 20 ml to synthesize cDNA using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems) according
to the manufacturer’s instructions. Real-time quantitative PCR
was conducted using the ViiATM 7 Real-Time PCR System
(Applied Biosystems) and performed in a total volume of 20 ml that
contained the TaqMan Gene Expression Master Mix (Applied
Biosystems), 1 ml of the cDNA template generated and the target-
specific TaqMan Gene expression assays (Applied Biosystems)
according to following cycle parameters: 95uC for 10 minutes
followed by 40 cycles at 95uC for 15 seconds and at 60uC for 1
minute. Each sample was run in triplicate using three biological
Table 3. List of mitochondria associated factors which are significantly altered as a result of hPNPaseold-35 stable knockdown, and
are associated with mitochondrial dysfunction, according to IPA Toxicogenomic Analysis.
Gene symbol Gene name Fold change Affymetrix ID
AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 21.11 *** 205512_s_at
APH1B anterior pharynx defective 1 homolog B (C. elegans) 21.37 ** 221036_s_at
BACE2 beta-site APP-cleaving enzyme 2 21.11 * 217867_x_at
CAT Catalase 21.45 *** 201432_at
CYB5R3 cytochrome b5 reductase 3 21.10 * 201885_s_at
GLRX2 glutaredoxin 2 21.28 * 219933_at
GPX4 glutathione peroxidase 4 1.21 * 201106_at
GSR glutathione reductase 21.31 * 205770_at
HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10 21.13 * 202282_at
MAP2K4 mitogen-activated protein kinase kinase 4 1.44 * 203266_s_at
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 21.15 * 200980_s_at
PSEN2 presenilin 2 (Alzheimer disease 4) 21.15 * 211373_s_at
PSENEN presenilin enhancer 2 homolog (C. elegans) 21.26 * 218302_at
SDHAP1 succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1 21.19 ** 222021_x_at
TRAK1 trafficking protein, kinesin binding 1 1.18 * 202080_s_at
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) 23.22 *** 208998_at
doi:10.1371/journal.pone.0076284.t003
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replicates and normalized to the housekeeping gene GAPDH used
as an internal control in each case. The DDCt method was used for
comparing relative fold expression differences in the genes of
interest between different test samples.
Protein isolation and Western blot analysis
Cells were harvested by centrifugation, pellets washed in PBS and
subsequently lysed in ice-cold 1X cell lysis buffer (Cell Signaling)
supplemented with PhosSTOP Phosphatase Inhibitor Cocktail
Tablets and complete Mini Protease Inhibitor Cocktail Tablets
(Roche), followed by centrifugation at 13,000 rpm for 15 minutes at
4uC. The supernatant or whole cell lysate was collected in a fresh
tube and protein concentration was measured using the Bio-Rad
Protein Assay Dye Reagent Concentrate (BIO-RAD). 30 mg of total
cell lysate was mixed with SDS sample buffer and heated for 5
minutes at 95uC. The proteins were separated by 8–10% SDS-
PAGE gels and transferred onto nitrocellulose membranes and
blocked using 5% non-fat milk supplemented with 1% bovine serum
albumin (BSA) in TBS-T for 1 hour. After washing three times with
TBS-T for 10 minutes each, the membranes were incubated with
primary antibodies overnight at 4uC. The primary antibodies used
were anti-hPNPaseold-35 (chicken; 1:5000), anti-EF1a (mouse,
1:1000). The next day membranes were washed as before and
incubated with the relevant horseradish-peroxidase conjugated
secondary antibodies for 1 hour at room temperature. After
washing three times with TBS-T for 10 minutes each, the proteins
were detected using ECL Western Blotting detection reagent (GE
Healthcare Life Sciences) and exposed to X-ray film.
Results
Melanoma cell culture model for studying hPNPaseold-35
regulated gene expression
In order to establish stable HO-1 human melanoma cell lines in
which hPNPaseold-35 expression was silenced, we employed a
Figure 4. Functional analysis of genes dysregulated as a result of hPNPaseold-35 overexpression. (A) The biological functions and states
associated with genes differentially expressed when hPNPaseold-35 is overexpressed in human melanoma cells. (B) Toxicologically related
functionalities and pathways associated with genes dysregulated (proportions shown in graphs) after hPNPaseold-35 overexpression in melanoma cells,
as identified by IPA Toxicogenomic Analysis.
doi:10.1371/journal.pone.0076284.g004
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lentiviral system to ensure efficient delivery. RNA and protein
levels of hPNPaseold-35 were analyzed in the different single clones
that survived after puromycin selection as described. Both the
shRNAs tested, PNPshRNA-1 (data shown for clone 4) and
PNPshRNA-2 (data shown for clone 9), resulted in $60%
knockdown at the protein level (Figure 1A) relative to the
scrambled control shRNA. PNPshRNA-1 clone 4 was used for
microarray analysis.
The replication-deficient adenovirus for ectopic overexpression
of hPNPaseold-35 has been extensively characterized previously
[7,11]. Infection of HO-1 cells was performed as previously
described [7,11] and both RNA and protein were analyzed for
overexpression of hPNPaseold-35 (Figure 1B). RNA from these cells
was collected 36 h post-infection for microarray analysis.
Genetic profile of hPNPaseold-35-knockdown melanoma
cells
In order to further understand and possibly identify novel
functions of hPNPaseold-35, we stably depleted it using shRNA in
HO-1 human melanoma cells (Figure 1A). The ability to study
changes in gene expression patterns has become a valuable
technique that permits evaluation of the significance of a gene in a
more global context. Microarray analysis between the hPNPaseold-35
shRNA and the scrambled shRNA expressing HO-1 cells led to
the identification of a total of 1025 upregulated and 1364
downregulated transcripts which were altered significantly (FDR
#0.05) (Figure 2).
We utilized IPA to functionally categorize all the differentially
expressed genes identified following hPNPaseold-35 knockdown in
HO-1 melanoma cells. Since the microarray experiments used to
identify the dysregulated pathways or networks affected after
hPNPaseold-35 depletion were based on a single shRNA, we cannot
claim that all these changes are truly an effect of hPNPaseold-35
depletion as there is a chance that some of these may be off-target
effects. Future studies based solely on the pathways or networks
identified here will need to be validated using multiple shRNAs or
hPNPaseold-35 wobble mutants. The main molecular and cellular
functions (p-values ranging from 3.92E-32 - 1.26E-03) associated
Table 4. List of genes which are significantly altered as a result of hPNPaseold-35 overexpression, and are functionally associated
with the maintenance of mitochondrial transmembrane potential, according to IPA Toxicogenomic Analysis.
Gene Symbol Gene Name Fold Change Affymetrix ID
APAF1 apoptotic peptidase activating factor 1 1.113** 211553_x_at
BARD1 BRCA1 associated RING domain 1 21.414** 205345_at
BCL2L11 BCL2-like 11 (apoptosis facilitator) 1.351** 222343_at
BIRC5 baculoviral IAP repeat containing 5 21.312** 202094_at
BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3 21.280** 201848_s_at
CD47 CD47 molecule 1.148** 213857_s_at
CHEK2 checkpoint kinase 2 21.387** 210416_s_at
CHMP5 charged multivesicular body protein 5 1.715** 218085_at
FAS Fas (TNF receptor superfamily, member 6) 1.450** 204781_s_at
IFI6 interferon, alpha-inducible protein 6 1.345** 204415_at
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 21.404** 209239_at
SLC25A14 solute carrier family 25 (mitochondrial carrier, brain), member 14 21.155** 204587_at
SOD2 superoxide dismutase 2, mitochondrial 1.384** 216841_s_at
TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 1.423** 201042_at
doi:10.1371/journal.pone.0076284.t004
Table 5. List of genes which are significantly altered as a result of hPNPaseold-35 overexpression, and are associated with G2/M DNA
damage checkpoint regulation, according to IPA Toxicogenomic Analysis.
Gene Symbol Gene Name Fold Change Affymetrix ID
BRCA1 breast cancer 1, early onset 21.235** 211851_x_at
CCNB2 cyclin B2 21.217** 202705_at
CDK1 cyclin-dependent kinase 1 21.496** 203214_x_at
CHEK2 checkpoint kinase 2 21.387** 210416_s_at
KAT2B K(lysine) acetyltransferase 2B 1.520** 203845_at
SKP1/SKP1P2 S-phase kinase-associated protein 1 1.173** 207974_s_at
YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta
polypeptide
21.139** 217717_s_at
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
polypeptide
1.332** 200639_s_at
doi:10.1371/journal.pone.0076284.t005
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with the most significantly altered genes were cell death and
survival, cellular growth and proliferation, protein synthesis, cell
cycle and RNA post-translational modification (Figure 3A, Table
S1A). Based on these functional categories 25 biological gene
networks were generated by IPA with a score ranging from 41 to
28 (Table S1D). IPA computes scores for each network based on
p-values, which in turn indicate the likelihood of genes being
found together in a network due to random chance. Higher the
score, lesser the chance of the genes in a network being grouped
together by random chance alone.
Apart from classifying individual genes into functional catego-
ries, IPA also predicts corresponding biological pathways that may
be significantly altered, along with mechanisms related to toxicity
at a more biochemical level (Figure 3). The most significant
canonical pathways identified were related to EIF2 signaling,
cholesterol biosynthesis, integrin signaling and mitochondrial
dysfunction (Figure S1A, Table S1C). Even more fascinating was
the finding that two of these biological pathways, cholesterol
biosynthesis (Table 1) and mitochondrial dysfunction (Tables 2
and 3), were directly correlated with predicted physiological
toxicity (identified through IPA-Tox analysis) (Figure 3B, Table
S1B). HMGCR (Figure S2A), HMGCS1 and IDI1 were the three
most significantly altered genes belonging to the cholesterol
biosynthesis pathway. An overall downregulation of genes
belonging to the electron transport chain and some associated
factors was observed, consistent with previous observations
regarding the role of hPNPaseold-35 in maintaining mitochondrial
homeostasis [9,23]. Some of the significantly downregulated genes
were NDUFA3, NDUFS1, UQCRFS1, COX6B1, C0X7A1, ATP5C1,
CAT and UCP2 (Figure S2B).
Gene expression profile of Ad.hPNPaseold-35-infected
melanoma cells
Overexpression of hPNPaseold-35 causes growth inhibition in a
number of cancer types and the growth prohibitive effects have
been attributed to the downregulation of c-myc RNA by
hPNPaseold-35. We performed a microarray analysis of HO-1 cells
infected with Ad.hPNPaseold-35 (Figure 1B) and compared the gene
expression changes to cells infected with Ad.vec to identify
transcripts differentially regulated as a result of hPNPaseold-35
overexpression. A total of 310 transcripts were upregulated and
407 were downregulated significantly (FDR#0.05) (Figure 2).
Significant gene expression changes associated with adenoviral
overexpression of hPNPaseold-35 could be classified into the
following molecular and cellular functional categories according
to IPA (p-values ranging from 7.50E-16 – 2.05E-03): cell cycle,
cellular growth and proliferation, cell death and survival, DNA
replication, recombination and repair and cellular development
(Figure 4A, Table S2A). Based on these functional categories 25
biological gene networks were generated by IPA with a score
ranging from 46 to 19 (Table S2D).
The following are the most significant biological pathways
altered when hPNPaseold-35 was overexpressed: hereditary breast
cancer signaling, p53 signaling, cell cycle control of chromosomal
replication, IGF-1 and EIF2 signaling (Figure S1B, Table S2C). In
order to understand if these pathways were relevant to any disease
phenotype, we made use of the IPA-Tox analysis which identified
p53 signaling, decreases Transmembrane Potential of Mitochon-
dria and Mitochondrial Membrane (Table 4) and Cell Cycle: G2/
M DNA Damage Checkpoint Regulation (Table 5) as some of the
predicted significantly affected mechanisms (Figure 4B, Table
S2B). The two main pathways we were interested to analyze
further were the ones involved with cell cycle regulation and
mitochondria, as there have been previous reports implicating a
role for hPNPaseold-35 in both these cellular functions [9,20].
Overexpression of hPNPaseold-35 causes growth inhibition, which is
partially attributed to downregulation of c-myc [11], so it was not
surprising to us when we observed changes in gene expression
related to cell cycle regulation. Some of the most significantly
altered genes in this category were CCNB2, CDK1, CHEK2 and
KAT2B (Table 5). Another interesting observation was the
dysregulation of mitochondrial homeostasis, which again empha-
sizes a role of hPNPaseold-35 in the mitochondria. These gene
expression changes could be due to a direct role that hPNPaseold-35
plays in the mitochondria or affects associated with growth
inhibition caused by hPNPaseold-35 overexpression. Some of these
significantly altered genes were FAS, BCL2L11 and BIRC5
(Table 4).
Identification of genes regulated by hPNPaseold-35
Bearing in mind that hPNPaseold-35 is functionally an exoribo-
nuclease, there could be two major mechanisms through which it
could modulate gene expression; it could either degrade target
genes directly (‘‘direct regulation’’) or it could degrade miRNAs (or
Table 6. Functional and structural categories of genes associated with hPNPaseold-35-driven regulation.
Functional category Source p-value no. of genes
‘‘Directly’’ regulated genes
RNA binding GO: Molecular Function 6.21E-05 13/894
Chromosome organization GO: Biological Process 1.28E-06 19/751
Cell cycle GO: Biological Process 1.28E-06 25/1460
Chromosome GO: Cellular Component 1.46E-10 21/671
Mitotic Prometaphase pathway MSigDB 3.62E-02 6/92
‘‘Indirectly’’ regulated genes
Response to wounding GO: Biological Process 5.43E-03 16/1168
Vacuole GO: Cellular Component 4.74E-03 9/424
Integral to plasma membrane GO: Cellular Component 4.81E-02 13/1328
CD molecules Gene Family (genenames.org) 3.45E-04 5/276
miR-124a MicroRNA (PicTar) 4.04E-02 11/626
doi:10.1371/journal.pone.0076284.t006
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mRNAs for other regulatory proteins) that in turn are regulators of
certain genes (‘‘indirect regulation’’). Since we had gene expression
patterns corresponding to both hPNPaseold-35 overexpression and
knockdown, we employed stringent criteria to identify genes that
could be directly or indirectly regulated by hPNPaseold-35 based on
the hypothesis we proposed. Instead of making the obvious choice
of selecting genes that were inversely related to the expression of
hPNPaseold-35 in either microarray dataset, we performed an
overlapping screen with the help of the online tool VENNY [42]
in order to identify transcripts whose expressions changed
inversely in both the datasets. This comparison resulted in the
identification of 77 potential hPNPaseold-35-directly regulated genes
that were up-regulated when hPNPaseold-35 was depleted and down-
regulated when hPNPaseold-35 was overexpressed (Figure 2B; Table
S3A, B). A second set of 61 transcripts that were downregulated
when hPNPaseold-35 was depleted by shRNA and up-regulated
when hPNPaseold-35 was overexpressed were also taken in consid-
eration as potential hPNPaseold-35-indirectly regulated genes
(Figure 2C; Table S3C, D). All the genes in these lists were
significant with q-values #0.05.
In order to place the hPNPaseold-35-regulated genes into
functional categories, we made use of the ToppFun function of
the ToppGene suite of web applications. A summary of the GO
categories with the maximum number of genes and the most
significant p-values is provided in Table 6. The hPNPaseold-35-
directly regulated genes represent significant enrichment related to
RNA binding, chromosome organization and cell cycle associated
(CENPE, MKI67, POLD3, MCM4) functions (Table S4A). To
determine how the hPNPaseold-35-regulated genes might interact
with each other, gene symbols were uploaded into GeneMANIA.
The directly regulated genes form a densely correlated network
with overlapping functional categories akin to organelle fission,
chromosome segregation and DNA strand elongation as predicted
by the gene functional analysis (Figure 5). IPA analysis of this gene
list also grouped the genes in similar biological categories
(Figure 6). There was an over-representation of genes related to
cellular response to wounding (TGM2, SDC2, MCAM), of genes
belonging to the CD family of cell surface receptors (DDR1, JAG1,
CD164, MCAM, CD47) and miR-124a predicted targets (SLC7A8,
JAG1, SDC2, CADM1, RNF128) in the hPNPaseold-35-indirectly
regulated genes dataset (Table S4B). These probe sets also form a
network cluster comprised mainly of co-expressed genes (Figure 7).
IPA analysis of this gene list grouped the genes into cellular
function and related categories (Figure 8). The inter-gene
Figure 5. Network visualization of genes potentially ‘‘directly’’ regulated by hPNPaseold-35.
doi:10.1371/journal.pone.0076284.g005
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correlations between probe sets defined as being potentially
directly or indirectly regulated by hPNPaseold-35 were largely based
on publically available co-expression association data.
In order to confirm select genes from the microarray analyses
(microarray fold changes provided in Table S3), five potential
hPNPaseold-35-regulated genes were validated (for the purpose of
this study we validated only a few genes as it was not feasible to
validate all the hPNPaseold-35-regulated genes identified) by
qRT-PCR to show their inverse correlation with hPNPaseold-35
expression in the HO-1 melanoma cell line as shown in Figure 9
(putative ‘‘direct target’’: CENPE; putative ‘‘indirect targets’’: VGF,
RNF128). CENPE was chosen for validation as it was also
identified in an overlapping screen we performed between
hPNPaseold-35-knockdown cells and a doxycycline inducible
hPNPaseold-35 overexpression system in HeLa cells (data not
shown). VGF and RNF128 were chosen as they showed the
maximum fold change in the hPNPaseold-35-knockdown cells. The
expression changes of four putative hPNPaseold-35-regulated genes
were also validated using another melanoma cell line WM35, in
which hPNPaseold-35 was stably knocked down using PNPsh1
Figure 6. Functional analysis hPNPaseold-35-putative ‘‘directly’’ regulated genes. (A) The biological functions and states associated with
hPNPaseold-35-putative ‘‘directly’’ regulated genes in human melanoma cells. (B) Toxicologically related functionalities and pathways associated with
hPNPaseold-35-putative ‘‘directly’’ regulated genes, as identified by IPA Toxicogenomic Analysis.
doi:10.1371/journal.pone.0076284.g006
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(Figures S3, S4 and S5). Transient knockdown of hPNPaseold-35
using siRNA (distinct from PNPsh1 and 2) also showed the
inverse correlation of hPNPaseold-35 expression with four putative
hPNPaseold-35-regulated genes (Figure S6) in HO-1 melanoma cells
(after 48 h). This trend was also observed in three other
melanoma cell lines, WM35, C8161 and MeWo, after silencing
hPNPaseold-35 transiently (Figures S7, S8 and S9).
Figure 7. Network visualization of genes potentially ‘‘indirectly’’ regulated by hPNPaseold-35.
doi:10.1371/journal.pone.0076284.g007
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Discussion
Numerous studies performed over the past decade have utilized
the RNAi methodology to evaluate the functions of hPNPaseold-35.
Most of these studies concentrated on studying the role of
hPNPaseold-35 in reference to its mitochondrial location with special
emphasis on mtRNA processing, maintenance of mitochondrial
homeostasis and more recently its role in mitochondrial RNA
import [9,23–27]. In other studies, overexpression of hPNPaseold-35
has been shown to cause growth inhibition attributed to
downregulation of c-myc and miR-221 by its exoribonuclease
activity in the cytosol [11,12]. In this study we have incorporated
both these classic genetic approaches of gene knockdown and
overexpression to further understand hPNPaseold-35 functions on a
more comprehensive level. This is the first attempt of its kind
aimed at studying global gene expression changes resulting from
hPNPaseold-35 knockdown or overexpression in order to identify
unique genes regulated by hPNPaseold-35. In this manuscript we
focus on the analysis of gene expression patterns of the most
relevant biological pathways of hPNPaseold-35 potential functions.
Figure 8. Functional analysis of hPNPaseold-35-putative ‘‘indirectly’’ regulated genes. (A) The biological functions and states associated with
hPNPaseold-35-putative ‘‘indirectly’’ regulated genes in human melanoma cells. (B) Toxicologically related functionalities and pathways associated with
hPNPaseold-35-putative ‘‘indirectly’’ regulated genes, as identified by IPA Toxicogenomic Analysis.
doi:10.1371/journal.pone.0076284.g008
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Our results show that stable knockdown of hPNPaseold-35 in
melanoma cells affects mitochondrial function and cholesterol
biosynthesis. Other groups have previously reported the
importance of hPNPaseold-35 in the maintenance of mitochondrial
homeostasis through knockdown and liver specific knockout
experiments where they showed a deregulation of the various
respiratory complexes in the Electron Transport Chain (ETC)
following hPNPaseold-35 silencing [9,23]. These results further
strengthen those findings. In this study we report novel genes
(Table 2) that encode for proteins constituting the various ETC
respiratory complexes, which were differentially expressed in our
hPNPaseold-35 knockdown melanoma cells. Some mitochondrial
accessory factors (Table 3) were also affected and one of them
UCP2 [43], which is a mitochondrial anion transporter that plays
a role in energy dissipation and maintenance of mitochondrial
membrane potential was downregulated ,3-fold (Figure S2B).
The exact mechanism of how hPNPaseold-35 regulates these genes
remains to be elucidated and the possibilities may be numerous
ranging from RNA degradation, miRNA regulation or RNA
import. Moreover, recently mutations in hPNPaseold-35 have also
been identified that impair respiratory-chain activity [44]. The
ETC genes identified in this study identify the specific genes
affected by hPNPaseold-35 that maybe causative for mitochondrial
dysfunction. Further studies aimed at understanding the func-
tional implications of the identified genes may provide valuable
insight to the physiological role of hPNPaseold-35 in mitochondrial
diseases and discovering suitable therapeutic options.
We also identified genes belonging to the cholesterol biosynthesis
pathway that were significantly downregulated with depletion of
hPNPaseold-35. This is a novel and potentially biologically important
result since association of hPNPaseold-35 with this pathway has not
been previously reported.Mitochondrial dynamics have been linked
to steroid biosynthesis and the gene expression changes we observed
pertaining to cholesterol biosynthesis could be a consequence of
mitochondrial dysfunction, or vice versa. Additionally, since this
analysis was performed in a stable cell line in which hPNPaseold-35was
silenced, certain compensatory changes could be acquired over time
as opposed to primary effects of gene knockdown. On the other
hand hPNPaseold-35 could indeed directly regulate the RNA levels of
these genes or alter their expression by regulating upstream
transcriptional control elements. SREBF2 is one such transcription
factor that was found to be downregulated 1.3-fold in our
microarray analyses which regulates the expression of HMGCR
(Figure S2A), HMGCS1 and IDI1. Further studies to address and
evaluate these possibilities would be required to assess the relevance
of hPNPaseold-35 in this context.
Previous studies have shown that adenoviral overexpression of
hPNPaseold-35 induces growth suppression and a senescence-like
phenotype [7,10]. Our present analyses show that the majority of
genes differentially expressed as a result of adenoviral overexpression
of hPNPaseold-35 compared to the empty vector control (Ad.Vec) belong
to cell cycle, cellular assembly and organization categories. Biological
pathways likely affected as a consequence of the gene expression
changes included cell cycle control of chromosomal replication. Key
genes down-regulated more than 1.5-fold in this category belonged to
the mini-chromosome maintenance complex (MCM2,MCM4-7) that
is essential for eukaryotic DNA replication. Important regulators of
G2/MDNA damage checkpoint control; CCNB2, CHEK2 and CDK1
were also downregulated. The gene expression changes of these cell-
cycle regulators may contribute towards tipping the balance in the
cell in the direction of growth inhibition. Also, changes in gene
expression were identified in apoptosis regulatory molecules. FAS,
BIK and BCL2L11 (pro-apoptotic) expression was increased and
BIRC5 (anti-apoptotic) levels were reduced significantly, which may
have played a role in decreasing the transmembrane potential of the
mitochondrial membrane observed upon hPNPaseold-35 overexpres-
sion in the IPA analyses, an important phenomenon implicated in
apoptosis [45]. These findings provide new information regarding the
cell-cycle associated implications of hPNPaseold-35 overexpression and
provide targets for further studies. These findings are also supported
by previous studies; where it was shown that terminal differentiation
(which shares overlapping characteristics with cellular senescence) of
HO-1 melanoma cells caused by combination treatment with IFN-b
plus the protein kinase C activator mezerein resulted in global gene
expression reductions of cell-cycle associated genes [46,47]. hPNPa-
seold-35 is a Type I-IFN inducible early response gene [8]; thus it was
not surprising that we observed a similar pattern of gene expression
changes in our present study involving hPNPaseold-35 overexpression.
The candidate genes identified may also provide insight regarding the
role of hPNPaseold-35 in aging-associated inflammation [21,22]. Some
of the potentially biologically significant genes in this category were
CAPN3, BIRC5, TRIM2, CENPF, FN1, BCL6 and GMNN. This
premise needs further attention, as it is evident that the cell-cycle
changes associated with hPNPaseold-35 overexpression are diverse and
complex. Also, c-myc is a key regulator of cell-cycle progression,
which is targeted by hPNPaseold-35 for degradation. Bearing this in
mind, in the present study we chose an earlier time point of 36 hours,
before changes in the c-myc transcript levels were evident (Figure
S10B), to study Ad.hPNPaseold-35 associated gene expression changes.
Even so, in order to identify genes directly targeted by hPNPaseold-35
irrespective of c-myc status we plan to study the effects of hPNPaseold-35
overexpression in a c-myc null background [48,49].
To identify additional genes regulated by hPNPaseold-35, we
ascertained transcripts in our two separate datasets (i.e. hPNPaseold-
35 knockdown and overexpression) whose expression inversely
correlated with hPNPaseold-35. This novel strategy helped us detect
77 potential ‘‘directly’’ (mRNA degraded by hPNPaseold-35) and 61
potential ‘‘indirectly’’ (miRNAs targeting these transcripts degraded
by hPNPaseold-35) regulated transcripts. Although in this study we
have concentrated on this small list of genes identified through the
overlapping approach between our hPNPaseold-35 depleted and
overexpression datasets, future studies would be required to
analyze the remaining genes whose expression is also regulated by
hPNPaseold-35 but do not fall in this list (Figures 2B-C). Most of these
potential ‘‘direct’’ targets were genes implicated in cell-cycle
associated functions and two of them have been validated by
qRT-PCR; CENPE (Centromere protein E) which is involved in
mitotic checkpoint control [50,51] and MKI67 (antigen identified
by monoclonal antibody Ki-67), a known cellular proliferation
marker implicated in rRNA synthesis [52-54]. Since most of the
genes thought to be ‘‘directly’’ regulated belong to a closely
associated network of cell cycle regulatory functions, at this point it
is difficult to say whether these gene expression changes represent
global effects of hPNPaseold-35 deregulation caused by key upstream
regulators or if they are genes that are directly targeted by
hPNPaseold-35 for degradation. Future studies using in vitro mRNA
degradation assays will help answer these questions. Among the
‘‘indirectly’’ regulated targets, a fraction of genes were identified that
had conserved sites for miR-124a (Table S4). We validated one of
these genes by qRT-PCR; RNF128 (ring finger protein 128) an E3
ubiquitin ligase that is involved in the regulation of cytokine gene
transcription [55]. Another potential indirect target we validated
was VGF (VGF nerve growth factor inducible), which encodes a
neuro-endocrine polypeptide implicated in a vast array of
biological phenomena that include energy metabolism and
inflammation [56-58]. Identification and subsequent validation
of miRNAs targeting the genes we identified would aid in
clarifying the role of hPNPaseold-35, if any, in the context of the
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relevant biological processes these genes are implicated in and
would further allow appropriate therapeutic intervention.
In summation, this study has produced a novel genetic and
genomic analysis of the functional implications for alterations in
PNPT1 gene expression. Our analysis has identified a limited set of
candidate genes for direct regulation by hPNPaseold-35. Such genes
could provide novel targets for intervention in hPNPaseold-35-related
disease states. Furthermore, this work has generated a comprehen-
sive database of hPNPaseold-35-responsive genes that are potentially
relevant to the mechanisms of global cellular functions affected by
this important regulatory molecule.
Supporting Information
Figure S1 Canonical pathways associated with genes
differentially expressed when hPNPaseold-35 is knocked
down (A) or overexpressed (B) in human melanoma
cells.
(TIF)
Figure S2 qRT-PCR verification of two most significant
genes associated with (A) cholesterol biosynthesis and
(B) mitochondrial dysfunction in hPNPaseold-35 silenced
HO-1 cells. Error bars represent mean 6 S.E. of three replicate
experiments.
(TIF)
Figure S3 Stable shRNA mediated knockdown and
overexpression of hPNPaseold-35 in WM35 melanoma
cells. (A) Phase contrast LM (top) and GFP fluorescent
micrographs (bottom) of WM35 melanoma cells following
transduction with GFP expressing scrambled shRNA and
hPNPaseold-35 shRNA1 expressing lentiviruses and selection with
Figure 9. Real time qRT-PCR validation of microarray findings. (A) qRT-PCR verification of hPNPaseold-35-putative ‘‘directly’’ regulated genes
identified by microarray analyses in response to hPNPaseold-35 (i) knockdown or (ii) overexpression in HO-1 melanoma cells. (B) qRT-PCR verification of
hPNPaseold-35-putative ‘‘indirectly’’ regulated genes identified by microarray analyses in response to hPNPaseold-35 (i) knockdown or (ii) overexpression
in HO-1 melanoma cells. Error bars represent mean 6 S.E. error of three replicate experiments.
doi:10.1371/journal.pone.0076284.g009
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puromycin. qRT-PCR expression of hPNPaseold-35 (hPNPaseold-35
knockdown) normalized to control (shScramble). Mean values
normalized to a GAPDH internal reference; error bars represent
mean 6 S.E. of three replicate experiments. Anti-hPNPaseold-35
and EF1a loading control immunoblots. (B) qRT-PCR expression
of hPNPaseold-35 in WM35 cells infected with Ad.hPNPaseold-35
normalized to cells infected with Ad.Vec for 36 h. Immunoblot
showing hPNPaseold-35 overexpression compared to Ad.Vec post
36 h of infection. Error bars represent mean 6 S.E. of three
replicate experiments. * P,0.02, ** P,0.01.
(TIF)
Figure S4 Real time qRT-PCR validation of hPNPaseold-35-
putative ‘‘directly’’ regulated genes. qRT-PCR verification
of hPNPaseold-35-putative ‘‘directly’’ regulated genes identified by
microarray analyses in response to hPNPaseold-35 (A) knockdown
or (B) overexpression in WM35 melanoma cells. Error bars
represent mean 6 S.E. of two replicate experiments done in
triplicate.
(TIF)
Figure S5 Real time qRT-PCR validation of hPNPaseold-35-
putative ‘‘indirectly’’ regulated genes. qRT-PCR verification
of hPNPaseold-35-putative ‘‘indirectly’’ regulated genes identified by
microarray analyses in response to hPNPaseold-35 (A) knockdown
or (B) overexpression in WM35 melanoma cells. Error bars
represent mean 6 S.E. of two replicate experiments done in
triplicate.
(TIF)
Figure S6 Real time qRT-PCR validation of microarray
findings in HO-1 melanoma cells. (A) qRT-PCR expression
of hPNPaseold-35 following transient transfection with siRNA against
hPNPaseold-35 normalized to scrambled control post 48 h in HO-1
melanoma cells. Immunoblot showing hPNPaseold-35 levels after
siRNA transfection. (B) qRT-PCR verification of hPNPaseold-35-
putative (i) ‘‘directly’’ and (ii) ‘‘indirectly’’ regulated genes after
hPNPaseold-35 transient silencing post 48 h. Error bars represent
mean 6 S.E. of two replicate experiments.
(TIF)
Figure S7 Real time qRT-PCR validation of microarray
findings in WM35 melanoma cells. (A) qRT-PCR expression
of hPNPaseold-35 following transient transfection with siRNA against
hPNPaseold-35 normalized to scrambled control post 48 h in WM35
melanoma cells. (B) qRT-PCR verification of hPNPaseold-35-
putative regulated genes after hPNPaseold-35 transient silencing post
48 h. Error bars represent mean 6 S.E. of two replicate
experiments.
(TIF)
Figure S8 Real time qRT-PCR validation of microarray
findings in C8161 melanoma cells. (A) qRT-PCR expression
of hPNPaseold-35 following transient transfection with siRNA against
hPNPaseold-35 normalized to scrambled control post 48 h in C8161
melanoma cells. Immunoblot showing hPNPaseold-35 levels after
siRNA transfection. (B) qRT-PCR verification of hPNPaseold-35-
putative regulated genes after hPNPaseold-35 transient silencing post
48 h. Error bars represent mean 6 S.E. of two replicate
experiments.
(TIF)
Figure S9 Real time qRT-PCR validation of microarray
findings in MeWo melanoma cells. (A) qRT-PCR expression
of hPNPaseold-35 following transient transfection with siRNA against
hPNPaseold-35 normalized to scrambled control post 48 h in MeWo
melanoma cells. Immunoblot showing hPNPaseold-35 levels after
siRNA transfection. (B) qRT-PCR verification of hPNPaseold-35-
putative regulated genes after hPNPaseold-35 transient silencing post
48 h. Error bars represent mean 6 S.E. of two replicate
experiments.
(TIF)
Figure S10 Effect of hPNPaseold-35 depletion or overex-
pression on c-mycmRNA levels. (A) qRT-PCR expression of
c-myc following hPNPaseold-35 stable knockdown in HO-1 melanoma
cells as identified in microarray analysis. (B) qRT-PCR expression
of c-myc following Ad.hPNPaseold infection post 36 h. Error bars
represent mean 6 S.E. of three replicate experiments.
(TIF)
Table S1 Results for IPA biological functions (A),
toxicity lists (B), canonical pathways (C) and most
significant networks (D) associated with genes dysreg-
ulated as a result of hPNPaseold-35 depletion.
(XLSX)
Table S2 Results for IPA biological functions (A),
toxicity lists (B), canonical pathways (C) and most
significant networks (D) associated with genes dysreg-
ulated as a result of hPNPaseold-35 overexpression.
(XLSX)
Table S3 Potential hPNPaseold-35 regulated genes. Genes
significantly regulated putatively by hPNPaseold-35 ‘‘directly’’ (A) & (B)
and ‘‘indirectly’’ (C) & (D).
(XLSX)
Table S4 Functional classification of hPNPaseold-35 pu-
tative ‘‘directly’’ (A) and putative ‘‘indirectly’’ (B)
regulated genes by ToppGene suite.
(XLSX)
Acknowledgments
DS is a Harrison Scholar in the VCU Massey Cancer Center and a
SWCRF Investigator. PBF holds the Thelma Newmeyer Corman Chair in
Cancer Research and is a SWCRF Investigator.
Author Contributions
Conceived and designed the experiments: UKS SD MFM DS PBF.
Performed the experiments: UKS CID. Analyzed the data: UKS CID
MFM PBF. Contributed reagents/materials/analysis tools: UKS MDB
SKD LE CID MFM. Wrote the paper: UKS PBF.
References
1. Arraiano C, Andrade J, Domingues S, Guinote I, Malecki M, et al. (2010) The
critical role of RNA processing and degradation in the control of gene
expression. FEMS Microbiol Rev 34: 883–923.
2. Deutscher MP, Li Z (2001) Exoribonucleases and their multiple roles in RNA
metabolism. Prog Nucleic Acid Res Mol Biol 66: 67–105.
3. Deutscher MP (1993) Ribonuclease multiplicity, diversity, and complexity. J Biol
Chem 268: 13011–13014.
4. Andrade J, Pobre V, Silva I, Domingues S, Arraiano C (2009) The role of 39-59
exoribonucleases in RNA degradation. Prog Mol Biol Transl Sci 85: 187–229.
5. Ibrahim H, Wilusz J, Wilusz CJ (2008) RNA recognition by 39-to-59
exonucleases: the substrate perspective. Biochim Biophys Acta 1779(4): 256–265.
6. Leszczyniecka M, DeSalle R, Kang DC, Fisher PB (2004) The origin of
polynucleotide phosphorylase domains. Mol Phylogenet Evol 31: 123–130.
7. Leszczyniecka M, Kang DC, Sarkar D, Su ZZ, Holmes M, et al. (2002)
Identification and cloning of human polynucleotide phosphorylase, hPNPaseold-35,
in the context of terminal differentiation and cellular senescence. Proc Natl Acad
Sci U S A 99: 16636–16641.
Genes Potentially Regulated by hPNPaseold-35
PLOS ONE | www.plosone.org 16 October 2013 | Volume 8 | Issue 10 | e76284
8. Leszczyniecka M, Su ZZ, Kang DC, Sarkar D, Fisher PB (2003) Expression
regulation and genomic organization of human polynucleotide phosphorylase,
hPNPaseold-35, a Type I interferon inducible early response gene. Gene 316:
143–156.
9. Chen H, Rainey R, Balatoni C, Dawson D, Troke J, et al. (2006) Mammalian
polynucleotide phosphorylase is an intermembrane space RNase that maintains
mitochondrial homeostasis. Mol Cell Biol 26: 8475–8487.
10. Rainey R, Glavin J, Chen H, French S, Teitell MA, et al. (2006) A new function
in translocation for the mitochondrial i-AAA protease Yme1: import of
polynucleotide phosphorylase into the intermembrane space. Mol Cell Biol
26: 8488–8497.
11. Sarkar D, Leszczyniecka M, Kang DC, Lebedeva IV, Valerie K, et al. (2003)
Down-regulation of Myc as a potential target for growth arrest induced by
human polynucleotide phosphorylase (hPNPaseold-35) in human melanoma cells.
J Biol Chem 278: 24542–24551.
12. Das SK, Sokhi UK, Bhutia SK, Azab B, Su ZZ, et al. (2010) Human
polynucleotide phosphorylase selectively and preferentially degrades microRNA-
221 in human melanoma cells. Proc Natl Acad Sci U S A 107: 11948–11953.
13. Sarkar D, Park ES, Barber G, Fisher PB (2007) Activation of double-stranded
RNA dependent protein kinase, a new pathway by which human polynucleotide
phosphorylase (hPNPaseold-35) induces apoptosis. Cancer Res 67: 7948–7953.
14. Chan I, Lebedeva IV, Su ZZ, Sarkar D, Valerie K, et al. (2008) Progression
elevated gene-3 promoter (PEG-Prom) confers cancer cell selectivity to human
polynucleotide phosphorylase (hPNPaseold-35)-mediated growth suppression.
J Cell Physiol 215: 401–409.
15. Van Maerken T, Sarkar D, Speleman F, Dent P, Weiss W, et al. (2009)
Adenovirus-mediated hPNPaseold-35 gene transfer as a therapeutic strategy for
neuroblastoma. J Cell Physiol 219: 707–715.
16. Das SK, Bhutia SK, Sokhi UK, Dash R, Azab B, et al. (2011) Human
polynucleotide phosphorylase (hPNPaseold-35): an evolutionary conserved gene
with an expanding repertoire of RNA degradation functions. Oncogene 30:
1733–1743.
17. Sarkar D, Park ES, Fisher PB (2006) Defining the mechanism by which IFN-
beta dowregulates c-myc expression in human melanoma cells: pivotal role for
human polynucleotide phosphorylase (hPNPaseold-35). Cell Death Differ 13:
1541–1553.
18. Sarkar D, Fisher PB (2006) Human polynucleotide phosphorylase (hPNPaseold-35):
an RNA degradation enzyme with pleiotrophic biological effects. Cell cycle 5:
1080–1084.
19. Sarkar D, Fisher PB (2006) Polynucleotide phosphorylase: an evolutionary
conserved gene with an expanding repertoire of functions. Pharmacology
therapeutics 112: 243–263.
20. Sokhi UK, Das SK, Dasgupta S, Emdad L, Shiang R, et al (2013) Human
polynucleotide phosphorylase (hPNPaseold-35): should I eat you or not- that is the
question? Advances in Cancer Research 119 (in press).
21. Sarkar D, Lebedeva IV, Emdad L, Kang DC, Baldwin AS, et al. (2004) Human
polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging
and inflammation. Cancer Res 64: 7473–7478.
22. Sarkar D, Fisher PB (2006) Molecular mechanisms of aging-associated
inflammation. Cancer Lett 236: 13–23.
23. Wang G, Chen H, Oktay Y, Zhang J, Allen E, et al. (2010) PNPASE regulates
RNA import into mitochondria. Cell 142: 456–467.
24. Wang G, Shimada E, Koehler CM, Teitell MA (2011) PNPASE and RNA
trafficking into mitochondria. Biochim Biophys Acta 1819: 998–1007.
25. Nagaike T, Suzuki T, Katoh T, Ueda T (2005) Human mitochondrial mRNAs
are stabilized with polyadenylation regulated by mitochondria-specific poly(A)
polymerase and polynucleotide phosphorylase. J Biol Chem 280: 19721–19727.
26. Slomovic S, Schuster G (2008) Stable PNPase RNAi silencing: its effect on the
processing and adenylation of human mitochondrial RNA. RNA 14: 310–323.
27. Yu Y, Chou R, Wu C, Wang Y, Chang W, et al. (2012) Nuclear EGFR
Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through
DNAPK-mediated Phosphorylation at Serine 776. J Biol Chem 287: 31015–
31026.
28. Chen H, Koehler CM, Teitell MA (2007) Human polynucleotide phosphorylase:
location matters. Trends Cell Biol 17: 600–608.
29. Giovanella BC, Stehlin JS, Williams LJ Jr (1974) Heterotransplantation of
human malignant tumors in ‘‘nude’’ thymusless mice. II. Malignant tumors
induced by injection of cell cultures derived from human solid tumors. J Natl
Cancer Inst 52(3):921–30.
30. Huberman E, Heckman C, Langenbach R (1979) Stimulation of differentiated
functions in human melanoma cells by tumor-promoting agents and dimethyl
sulfoxide. Cancer Res 39: 2618–2624.
31. Fisher PB, Prignoli DR, Hermo H, Weinstein IB, Pestka S (1985) Effects of
combined treatment with interferon and mezerein on melanogenesis and growth
in human melanoma cells. J Interferon Res 5: 11–22.
32. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, et al. (1985)
Characteristics of cultured human melanocytes isolated from different stages of
tumor progression. Cancer Res 45: 5670–5676.
33. Balaban G, Herlyn M, Guerry D IV, Bartolo R, Koprowski H, et al. (1984)
Cytogenetics of human malignant melanoma and premalignant lesions. Cancer
Genet Cytogenet 11: 429–439.
34. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, et al. (2001)
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte
growth factor during melanoma development. Oncogene 20(56):8125–35.
35. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, et al. (1995) The melanoma
differentiation-associated gene mda-6, which encodes the cyclin-dependent
kinase inhibitor p21, is differentially expressed during growth, differentiation and
progression in human melanoma cells. Oncogene 10(9):1855–64.
36. Dumur CI, Ladd AC, Wright HV, Penberthy LT, Wilkinson DS, et al. (2009)
Genes involved in radiation therapy response in head and neck cancers.
Laryngoscope 119: 91–101.
37. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biology 5: R80.
38. Gatta V, Drago D, Fincati K, Valenti MT, Dalle Carbonare L, et al. (2011)
Microarray analysis on human neuroblastoma cells exposed to aluminum, b (1-
42)-amyloid or the b (1-42)-amyloid aluminum complex. PloS One 6(1): e15965.
39. Redmond LC, Dumur CI, Archer KJ, Haar JL, Lloyd JA (2008) Identification of
erythroid-enriched gene expression in the mouse embryonic yolk sac using
microdissected cells. Developmental Dynamics 237: 436–446.
40. Chen J, Bardes EE, Aronow BJ, Jegga AG (2009) ToppGene Suite for gene list
enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37:
W305–W311.
41. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, et al. (2010)
The GeneMANIA prediction server: biological network integration for gene
prioritization and predicting gene function. Nucleic Acids Research 38: W214–
W220.
42. Oliveros J.C. (2007) VENNY. An interactive tool for comparing lists with Venn
Diagrams. Available: http://bioinfogp.cnb.csic.es/tools/venny/index.html. Ac-
cessed 2013 Aug 29.
43. Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, et al. (2000)
Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity
and reactive oxygen species production. Nat Genet 26(4): 435–439.
44. Vedrenne V, Gowher A, De Lonlay P, Nitschke P, Serre V, et al. (2012)
Mutation in PNPT1, which encodes a polyribonucleotide nucleotidyltransferase,
impairs RNA import into mitochondria and causes respiratory-chain deficiency.
Am J Hum Genet 91(5): 912–918.
45. Gottlieb E, Armour SM, Harris MH, Thompson CB (2003) Mitochondrial
membrane potential regulates matrix configuration and cytochrome c release
during apoptosis. Cell Death Differ 10(6): 709–717.
46. Huynh KM, Kim G, Kim DJ, Yang SJ, Park SM, et al. (2009) Gene expression
analysis of terminal differentiation of human melanoma cells highlights global
reductions in cell cycle-associated genes. Gene 433: 32–39.
47. Staudt MR, DePass AL, Sarkar D, Fisher PB (2009) Model cell culture system
for defining the molecular and biochemical events mediating terminal
differentiation of human melanoma cells. J Cell Physiol 218: 304–314.
48. Obaya MM, Mateyak MK, Obaya AJ, Adachi S, Sedivy JM (1997) Phenotypes
of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombina-
tion; Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted
homologous recombination. Cell Growth Differ 8(10): 1039–1048.
49. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, et al. (1998) c-myc null cells
misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev
12(24): 3797–3802.
50. Yen TJ, Compton DA, Wise D, Zinkowski RP, Brinkley BR, et al. (1991) CENP-
E, a novel human centromere-associated protein required for progression from
metaphase to anaphase. EMBO J 10(5): 1245–1254.
51. Tanudji M, Shoemaker J, L’Italien L, Russell L, Chin G, et al. (2004) Gene
silencing of CENP-E by small interfering RNA in HeLa cells leads to
missegregation of chromosomes after a mitotic delay. Mol Biol Cell 15(8):
3771–3781.
52. Scholzen T, Gerdes J (2000) The Ki-67 protein: From the known and the
unknown. J Cell Physiol 182: 311–322.
53. Bullwinkel J, Baron-Lu¨hr B, Lu¨demann A, Wohlenberg C, Gerdes J, et al. (2006)
Ki-67 protein is associated with ribosomal RNA transcription in quiescent and
proliferating cells. J Cell Physiol 206: 624–635.
54. Rahmanzadeh R, Hu¨ttmann G, Gerdes J, Scholzen T (2007) Chromophore-
assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA
synthesis. Cell Prolif 40(3): 422–430.
55. Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, et al. (2003)
GRAIL: An E3 Ubiquitin Ligase that Inhibits Cytokine Gene Transcription Is
Expressed in Anergic CD4+ T Cells. Immunity 18: 535–547.
56. Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, et al. (1999) Targeted
Deletion of the Vgf Gene Indicates that the Encoded Secretory Peptide
Precursor Plays a Novel Role in the Regulation of Energy Balance. Neuron 23:
537–548.
57. Rizzi R, Bartolomucci A, Moles A, D’Amato F, Sacerdote P, et al. (2008) The
VGF-derived peptide TLQP-21: A new modulatory peptide for inflammatory
pain. Neurosci Lett 441: 129–133.
58. Ferri G, Noli B, Brancia C, D’Amato F, Cocco C (2011) VGF: An inducible
gene product, precursor of a diverse array of neuro-endocrine peptides and
tissue-specific disease biomarkers. J Chem Neuroanat 42: 249–261.
Genes Potentially Regulated by hPNPaseold-35
PLOS ONE | www.plosone.org 17 October 2013 | Volume 8 | Issue 10 | e76284
